Crossmark

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Crossref DOI link: https://doi.org/10.1186/s40425-019-0655-4

Published Online: 2019-07-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Glutsch, Valerie

Grän, Franziska

Weber, Judith

Gesierich, Anja

Goebeler, Matthias

Schilling, Bastian https://orcid.org/0000-0001-8859-4103
License Information

Text and Data Mining valid from 2019-07-12
More Information

Article History

Received: 1 March 2019

Accepted: 27 June 2019

First Online: 12 July 2019

Ethics approval and consent to participate

: Not Appliclable.

: Formal consent for anonymous publication of retrospective data from routine care is not required by local laws.

: Valerie Glutsch reports travel support from Novartis, Pierre Fabre Pharmaceuticals, Bristol-Myers Squibb (BMS) and Merck Sharp & Dohme (MSD).Judith Weber reports travel support from BMS and MSD.Anja Gesierich reports advisory roles for BMS, MSD, Novartis, Roche, Pfizer, Sanofi Genzyme, has received honoraria from MSD and BMS, and travel support from BMS, MSD, Novartis and Roche.Bastian Schilling reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS and MSD, research funding from BMS, Pierre Fabre Pharmaceuticals and MSD, and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals and Amgen.All other authors declare no conflicts of interest.